{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-049658","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2024-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.764699+00:00","generated_at":"2026-06-01T06:31:39.283107+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silo Pharma submits pre-IND to FDA for SPC-15 intranasal PTSD treatment","bullets":["SPC-15 is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder.","Pre-clinical data showed effective, consistent exposure in a non-GLP small animal study completed Feb 2024.","Silo expects to finalize an exclusive worldwide license with Columbia University in H1 2024.","Next steps: PIND and GLP studies both slated to commence in H2 2024 before IND submission.","Only two FDA-approved PTSD drugs exist; SPC-15 aims to increase stress resilience in high-risk populations."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-049658","json":"https://secwatch.observer/filing/0001213900-24-049658.json","markdown":"https://secwatch.observer/filing/0001213900-24-049658.md","text":"https://secwatch.observer/filing/0001213900-24-049658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024049658/0001213900-24-049658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024049658/ea0207247-8k_silo.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:31:39.283107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}